Ideaya Biosciences Begins Phase 1 Trial for IDE892
Ideaya Biosciences announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, a methylthioadenosine-cooperative inhibitor of PRMT5, in combination with IDE397, an inhibitor of MAT2A, in MTAP-deleted solid tumors, with a focus on NSCLC and pancreatic cancer. In preclinical studies, dual inhibition of PRMT5 and MAT2A with the combination of IDE892 and IDE397 resulted in potent anti-tumor activity in MTAP-deleted tumor models, including complete and durable responses at well-tolerated doses below those required for monotherapy activity.
